# DiagnosTear

其 TearX 平台近期报告了中期临床研究结果，显示其 Red Eye 检测与定量ELISA检测之间具有极佳的相关性，同时获得法国监管批准，并与 Alyatec 启动了一项新的临床研究。

Source: https://cn.bioecon.ru/companies/diagnostear/
Updated: 2026-07-20

- 国家: France

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 2025 年 11 月完成 925,000 加元的私募股权轮融资 | https://www.marketscreener.com/news/diagnostear-announces-regulatory-approvals-in-france-and-study-initiation-with-alyatec-for-tearx-tm-ce7e5cd9d18ef225, https://www.newsfilecorp.com/company/11754/DiagnosTear-Technologies-Inc. |
| 融资 | 2025 年 10 月完成 100 万美元的私募股权轮融资 | https://www.marketscreener.com/news/diagnostear-announces-regulatory-approvals-in-france-and-study-initiation-with-alyatec-for-tearx-tm-ce7e5cd9d18ef225, https://www.newsfilecorp.com/company/11754/DiagnosTear-Technologies-Inc. |
| 融资 | 2025年6月宣布的700,000加元私募股权融资 | https://www.marketscreener.com/news/diagnostear-announces-regulatory-approvals-in-france-and-study-initiation-with-alyatec-for-tearx-tm-ce7e5cd9d18ef225, https://www.newsfilecorp.com/company/11754/DiagnosTear-Technologies-Inc. |
| 产能 | 已完成注塑模具，可生产100,000台TeaRx Red Eye设备；通过股东Elcam，公司可获得数百万台的潜在产能 | https://diagnostear.com/, https://news.futunn.com/resource/11262102, https://stockhouse.com/news/newswire/2025/12/15/diagnostear-a-diagnostic-technology-stock-forefront-ocular-disease |
| 认证 | TeaRx Dry Eye持有CE-IVD认证 | https://diagnostear.com/ |
| 监管批准 | 截至2026年2月,TeaRx Red Eye临床研究已在法国获得监管及伦理批准 | https://www.marketscreener.com/news/diagnostear-announces-regulatory-approvals-in-france-and-study-initiation-with-alyatec-for-tearx-tm-ce7e5cd9d18ef225 |
| 营收 | 公司处于收入前阶段，年收入维持在低于$10 million | https://stockhouse.com/news/newswire/2025/12/15/diagnostear-a-diagnostic-technology-stock-forefront-ocular-disease, https://www.barchart.com/story/news/1434996/diagnostear-technologies-inc-announces-adoption-of-semi-annual-reporting |

独立来源: barchart.com, marketscreener.com, news.futunn.com, newsfilecorp.com, stockhouse.com

## 技术

- [泪液活检](https://cn.bioecon.ru/technology/tear-fluid-biopsy/)